Fallout from the merger that might be

Article Abstract:

Hoechst and Rhone-Poulenc have announced their intention to form a new company called Aventis by merging their respective life sciences activities in agriculture, pharmaceuticals, and veterinary medicine. The new company would employ some 95,000 people worldwide, would have an R&D budget of about $3 billion and estimated total sales in excess of $20 billion. Analysts believe that Aventis' parent companies decided to merge out of mutual need; both companies need to capitalize on innovation, particularly in genomics and bioengineering. Article includes a table showing Rhone and Hoechst recent biotechnology deals.

France, Chemicals & Allied Products, Chemical Manufacturing, Chemicals, Aventis S.A., Rhone-Poulenc S.A., Hoechst AG

---

LION and Degussa apply genomics to fermentation

Article Abstract:

LION Bioscience and Degussa will collaborate in an effort to analyze and sequence the genome of a wide-type strain of the amino acid-producing organism, Corynebacterium glutamicum (C. glutamicum). LION will sequence an ordered overlapping cosmid library. Alfred Puhler, who constructed the cosmid library, believes that the sequencing work will reach completion by the close of 1998. The next phase of the study is devoted to the identification of mutations that have given rise to the high-yielding production strains of C. glutamicum that are used industrially.

Comment:

LION Bioscience, Degussa will collaborate in sequencing genome of C. glutamicum.

Science & research, Medicinal and Botanical Manufacturing, Amino Acids, Bulk amino acids, LION bioscience AG, Article

---

Celltech, Chiroscience fire merger gun

Article Abstract:

Slough, England-based Celltech and Cambridge, England-based Chiroscience will merge. The move will bring relief to the UK's troubled biotechnology sector. The joint company will be valued at US$1 billion. Celtech will acquire Chiroscience. The terms of the deal have not been finalized.

United Kingdom, Asset sales & divestitures, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Celltech Group PLC, Chiroscience Group PLC

Similar abstracts:

• Abstracts: Ways to tap the best in Peps by phone. Closing the gap. Performance reporting that needs to be pepped up
• Abstracts: Funds for all the family. Investors must be choosers. Cashing in on Pep allowances
• Abstracts: Small, but imperfectly formed. Now is the time to be more critical. The first season of goodwill
• Abstracts: The role of fruit in the Japanese gift market: situationally defined markets. Overcoming informal trade barriers among Japanese intermediaries: An attitudinal assessment
• Abstracts: The economics of prepaying wealth transfer tax. The value of key-person life insurance for estate tax planning

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.